Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial

被引：0
|
作者：
Krempf, M. [1 ]
Astrup, A. [2 ]
le Roux, C. [3 ]
Fujioka, K. [4 ]
Greenway, F. [5 ]
Halpern, A. [6 ]
Lau, D. C. W. [7 ]
Violante Ortiz, R. [8 ]
Wilding, J. P. H. [9 ]
Jensen, C. B. [10 ]
Lillleore, S. K. [10 ]
Pi-Sunyer, X. [11 ]
机构：
[1] CHRU Nantes, Clin Endocrinol, Nantes, France
[2] Univ Copenhagen, DK-1168 Copenhagen, Denmark
[3] Univ Coll Dublin, Dublin, Ireland
[4] Scripps Clin, La Jolla, CA USA
[5] Louisiana State Univ, Baton Rouge, LA 70803 USA
[6] Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil
[7] Univ Calgary, Calgary, AB T2N 1N4, Canada
[8] Inst Mexicano Seguro Social, Ciudad Madero, Mexico
[9] Univ Liverpool, Liverpool L69 3BX, Merseyside, England
[10] Novo Nordisk AS, Soborg, Denmark
[11] Columbia Univ, New York, NY USA
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
903
引用
收藏
页码：S368 / S368
页数：1
相关论文
共 50 条
  • [21] A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial
    McKay, Diane L.
    Eliasziw, Misha
    Chen, C. Y. Oliver
    Blumberg, Jeffrey B.
    NUTRIENTS, 2018, 10 (03)
  • [22] Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial
    Madsbad, S.
    Lieberman, G.
    Skjoth, T. V.
    Lilleore, S. K.
    DeFronzo, R. A.
    DIABETOLOGIA, 2016, 59 : S40 - S41
  • [23] Rimonabant improves body weight and cardiometabolic risk factors in older adults
    Aronne, Louis J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 325A - 325A
  • [24] Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg (STEP 8)
    Rubino, D. M.
    Garvey, T. W.
    Goldman, B.
    Khalid, U.
    Rosenstock, J.
    Sorrig, R.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S287 - S288
  • [25] Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg (STEP 8)
    Idris, Iskandar
    Rubino, Domenica
    Garvey, W. Timothy
    Goldman, Bryan
    Khalid, Usman
    Rosenstock, Julio
    Sorrig, Rasmus
    OBESITY SURGERY, 2023, 33 : S39 - S39
  • [26] Lifestyle intervention reduces body weight and improves cardiometabolic risk factors in worksites
    Salinardi, Taylor C.
    Batra, Payal
    Roberts, Susan B.
    Urban, Lorien E.
    Robinson, Lisa M.
    Pittas, Anastassios G.
    Lichtenstein, Alice H.
    Deckersbach, Thilo
    Saltzman, Edward
    Das, Sai Krupa
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2013, 97 (04): : 667 - 676
  • [27] Effect of liraglutide 3.0 mg on glycaemic parameters in adults with overweight/obesity and type 2 diabetes treated with basal insulin: SCALE insulin trial
    Dicker, D.
    Birkenfeld, A. L.
    Garvey, T.
    Mingrone, G.
    Pedersen, S. D.
    Satylganova, A.
    Skovgaard, D.
    Sugimoto, D.
    Zeuthen, N.
    Mosenzon, O.
    DIABETOLOGIA, 2019, 62 : S277 - S278
  • [28] Semaglutide 2.4 mg Improved Glucose Metabolism and Reverted Prediabetes to Normoglycemia in Adults with Overweight/Obesity vs. Liraglutide 3.0 mg (STEP 8)
    Rosenstock, Julio
    Garvey, W. Timothy
    Goldman, Bryan
    Khalid, Usman
    Sorrig, Rasmus
    Rubino, Domenica
    DIABETES, 2022, 71
  • [29] Effectiveness and safety of liraglutide 3.0 and 1.8mg in weight loss responders among adults with overweight/obesity with Type 2 diabetes: SCALE Diabetes Trial subgroup analysis
    Davies, M.
    DeFronzo, R.
    Bergenstal, R.
    Kushner, R.
    Skjoth, T.
    Claudius, B.
    Mosenzon, O.
    DIABETIC MEDICINE, 2017, 34 : 77 - 77
  • [30] Efficacy and safety of liraglutide 3.0 mg and 1.8 mg in weight loss responders vs non-responders in overweight/obese adults with Type 2 diabetes: a subgroup analysis of the SCALE Diabetes trial
    Davies, M. J.
    DeFronzo, R.
    Bergenstal, R.
    Kushner, R.
    Skjoth, T. V.
    Nzeakor, N.
    Mosenzon, O.
    DIABETIC MEDICINE, 2016, 33 : 65 - 65
12345